Non-Hodgkin Lymphoma - Heat Map and Analysis

ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing) or aggressive (fast-growing). Almost 85% of NHLs are of B-cell origin, while 15% are derived from T/natural killer cells. The small remainder stem from macrophages. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common types of NHL, representing over 50% of cases.

Scope of the Report:

- How is the NHL market landscape expected to change with the uptake of promising novel pipeline products and products that have been recently approved?

- What are the clinical characteristics of currently approved therapies for NHL, in terms of specific safety and efficacy parameters?

- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?

- What treatment line settings have the greatest unmet need for pipeline drugs to fill?

- Which pipeline drugs have shown the strongest efficacy in clinical trials, and how do these compare to clinical trials of currently marketed drugs?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6876

Reasons to buy

- Understand the current clinical landscape by considering the treatment options available for each patient segment.

- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.

- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.

- Understand the relative strengths and weaknesses of the studies used to gather data.

- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.

- Assess your own pipeline programs in light of these benchmarks in order to optimally position them, and maximize uptake by clinicians.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/non-hodgkin-lymphoma-heat-map-and-analysis

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.